ONCOLOGY Vol 36, Issue 2

Nora Janjan, MD, MPSA, MBA, gives her perspective on oncology drug development through academic promotion, as an accompaniment to the article titled "Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and Oncology" published in the journal ONCOLOGY.

Conflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.

Jonathan R. Day, MD, PharmD, and Brian K. Link, MD, give their perspective on emerging treatments for follicular lymphoma.

This review article written by Kirk E. Cahill, MD, and Sonali M. Smith, MD, discusses standard and emerging therapies for the treatment of follicular lymphoma.

This review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.

“The pendulum is moving fast towards giving chemotherapy prior to surgery, and the research is going on to continue that trend.”

In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of mobocertinib as therapy for patients with lung cancer.

ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, re-caps the 2021 American Society of Hematology conference and discusses which presentations were the most important.